Factrel

(Gonadorelin)

ApprovedSmall molecule

Ferring

Factrel is one of 90 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Polycystic Ovary SyndromeUnknown status

AdolescentUnknown status

Postmenopausal WomenActive, not recruiting

Sleep RestrictionActive, not recruiting

Polycystic Ovary SyndromeApproved

Unknown status

AdolescentPreclinical

Unknown status

Postmenopausal WomenPhase 1

Active, not recruiting

Sleep RestrictionPhase 1

Active, not recruiting

Competition

Competitive Landscape

71 competitors in Polycystic Ovary Syndrome

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

6 2

Ozempic

Novo Nordisk

Approved

2 3

Avandia

Jazz Pharmaceuticals

Approved

2 4

Evista

Calciferol

Onglyza

Glucophage

3 8

Gynorest

SSolvay Pharmaceuticals

Approved

1 9

Zocor

OOrganon and Co

Approved

1 10

Orgalutran

OOrganon and Co

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postmenopausal Women1 trial

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Active, not recruiting·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 1·NCT04037605·5 enrolled

Polycystic Ovary Syndrome1 trial

Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome

Unknown status·RRenJi Hospital·Phase 4·NCT03989024·78 enrolled

Adolescent1 trial

Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

Unknown status·HHuashan Hospital·N/A·NCT05184374·20 enrolled

Sleep Restriction1 trial

Hormonal Mechanisms of Sleep Restriction - Axis Study

Active, not recruiting·PPeter y. Liu·Phase 1·NCT03142893·80 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 30, 1982

FACTREL

NDA NDA018123

Oct 10, 1989

LUTREPULSE KIT

NDA NDA019687

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Gonadorelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gonadorelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gonadorelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019687). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Ferring

Factrel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postmenopausal Women1 trial

Polycystic Ovary Syndrome1 trial

Adolescent1 trial

Sleep Restriction1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News